Tatsis Nia, Ertl Hildegund C J
The Wistar Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.
Mol Ther. 2004 Oct;10(4):616-29. doi: 10.1016/j.ymthe.2004.07.013.
Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. Additionally, they are being explored as vaccines against a multitude of tumor-associated antigens. In this review we describe the molecular biology of adenoviruses as well as ways the adenovirus vectors can be manipulated to enhance their efficacy as vaccine carriers. We describe methods of evaluating immune responses to transgene products expressed by adenoviral vectors and discuss data on adenoviral vaccines to a selected number of pathogens. Last, we comment on the limitations of using human adenoviral vectors and provide alternatives to circumvent these problems. This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens.
腺病毒已从基因替代疗法的工具转变为真正的疫苗递送载体。它们是有吸引力的疫苗载体,因为它们能在哺乳动物宿主中诱导先天性和适应性免疫反应。目前,腺病毒载体正作为亚单位疫苗系统,针对从疟疾到HIV-1等多种感染因子进行测试。此外,它们也正在被探索作为针对多种肿瘤相关抗原的疫苗。在这篇综述中,我们描述了腺病毒的分子生物学,以及操纵腺病毒载体以提高其作为疫苗载体功效的方法。我们描述了评估对腺病毒载体表达的转基因产物免疫反应的方法,并讨论了针对选定数量病原体的腺病毒疫苗的数据。最后,我们评论了使用人腺病毒载体的局限性,并提供了规避这些问题的替代方案。这个领域正以令人兴奋的速度快速发展,因此我们将范围限制在使用腺病毒载体作为针对病毒病原体的疫苗。